Showing posts with label Heart. Show all posts
Showing posts with label Heart. Show all posts

Wednesday, May 19, 2010

Processed meat may be linked to increased risk of heart disease, diabetes

Moral of the story: Processed meat may the real culprit and unprocessed red meat may be less unhealthy than previously thought. maybe.

Source: AMA Morning Rounds 5/18/2010

Processed meat may be linked to increased risk of heart disease, diabetes.

The Wall Street Journal (5/18, Winslow) reports that processed meat may be linked to increased risk of heart disease and diabetes, according to a study published online in the journal Circulation.
        The Boston Globe (5/17, Cooney) "White Coat Notes" blog reported that investigators looked at data from "20 studies involving more than 1.2 million participants from 10 countries who were followed for up to 18 years." After "pooling the study results, the researchers found that eating unprocessed red meat was not associated with heart disease or diabetes." However, "people who ate at least one serving a day of processed red meat -- one hot dog or two deli slices -- had a 42 percent higher risk of heart disease and a 19 percent higher risk of diabetes than people who did not eat processed red meat."

Wednesday, January 6, 2010

Breast-feeding may benefit a woman's heart.

Moral of the story: Again, another benefit to breast-feeding.

Source: AMA Morning Rounds 12/22/09

Breast-feeding may benefit a woman's heart.


HealthDay (12/21, Gordon) reported that breast-feeding may help protect a woman's heart, according to research scheduled to be published in Obstetrics and Gynecology. Investigators, "in a study of nearly 300 women," employed "two imaging techniques -- electron beam tomography and ultrasound -- to assess the health of the women's blood vessels." The researchers "found that 32 percent of the women who had not breast-fed had coronary artery calcification, compared with 17 percent of the breast-feeding moms."

Sunday, November 29, 2009

Researchers associate low levels of vitamin D with CAD, stroke, heart failure.

Moral of the story: There is a link between the chronic, prevalent low vitamin D levels in the US and all those cardiovascular problems. It may be a tough balance between skin cancer and vitamin D, but the importance of the vitamin D is becoming more clear.

Source: AMA Morning Rounds 11/17/09

Researchers associate low levels of vitamin D with CAD, stroke, heart failure.

The New York Times (11/16, Rabin) "Well" blog reported that, according to research presented Nov. 16 at the American Heart Association conference, "Americans aren't getting anywhere nearly enough of" vitamin D, "and it may be affecting their heart health." After examining data on 27,686 "healthy adults 50 and older whose vitamin D levels had been measured during routine checkups," researchers found that "those who had extremely low levels of the vitamin were almost twice as likely to have died or suffered a stroke than those with adequate amounts." In addition, they "had more coronary artery disease and were twice as likely to have developed heart failure." HealthDay (11/16, Preidt) and CNN (11/17, Mann) also cover the study.

FDA warns against concomitant use of Plavix, certain heartburn drugs.

Moral of the story: If you are taking these two drugs (blood thinners and proton-pump inhibitors for heartburn) talk to your doctor. You need to up the dosage of the blood thinner.

Source: AMA Morning Rounds 11/18/09

FDA warns against concomitant use of Plavix, certain heartburn drugs.

NBC Nightly News (11/17, story 2, 0:40, Williams) reported that "millions of Americans take" Plavix (clopidogrel) "to reduce the risk of heart attacks and strokes." But, because the blood thinner "can upset the stomach, it is often prescribed alongside drugs like Prilosec (omeprazole) and Nexium (esomeprazole)." Now, however, the FDA is warning that those popular medications can "weaken the effect of Plavix."

In fact, the "anti-clotting benefits of Plavix are cut almost in half when taken with over-the-counter or prescription Prilosec, according to a notice posted today on the Food and Drug Administration's website," Bloomberg News (11/18, Larkin) reports. Thus, the "agency ordered Paris-based Sanofi and New York-based Bristol-Myers to update the prescribing information for Plavix and study the potential for other drug interactions." Although the "Plavix prescribing information was updated in January to discourage use with Prilosec," the latest warning includes the those two PPIs and nine other "similar drugs."

However, the agency "did not have enough information to say whether other drugs in the same class as Nexium and Prilosec...also react adversely with Plavix," the Los Angeles Times (11/18, Zajac) reports. "This includes such drugs as Prevacid [lansoprazole] and Protonix [pantoprazole]."

Nevertheless, those who still "need to reduce their acid should take drugs from the H-2 blocker family, which include Johnson & Johnson's Mylanta [aluminum hydroxide/magnesium hydroxide/simethicone] and Boehringer Ingelheim's Zantac [ranitidine]," the AP (11/18, Perrone) reports. "FDA scientists say there is no evidence those drugs interfere with Plavix's blood clotting." As for the omeprazole, the FDA decided to strengthen its warning after reviewing "a 150-patient study submitted by Sanofi over the summer."

That report indicated that drugs like Nexium reduce the production of an enzyme -- CYP 2C19 -- that sets Plavix in motion, according to the Wall Street Journal (11/18, Mundy). Several other drugs, WebMD (11/17, DeNoon) reported, "also inhibit CYP 2C19, and the FDA says patients on Plavix should avoid them as" well: Tagamet (cimetidine), Luvox (fluvoxamine), Ticlid (ticlopidine), Diflucan (fluconazole), Nizoral (ketoconazole), VFEND (voriconazole), Intelence (etravirine), Felbatol (felbamate), and Prozac, Serafem, and Symbyax (fluoxetine).

HealthDay (11/17, Reinberg), Dow Jones Newswire (11/17, Favole), and CQ HealthBeat (11/18) also covered the story

High salt intake directly linked to stroke and cardiovascular disease

Moral of the story: Eat less salt. That's it. Your heart will thank you.

Source: BMJ press releases Monday 23 November to Friday 27 November 2009. Available in full at www.bmj.com

(1) High salt intake directly linked to stroke and cardiovascular disease

(Research: Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies)
http://www.bmj.com/cgi/doi/10.1136/bmj.b4336
(Editorial: The case for population-wide salt reduction gets stronge)
http://www.bmj.com/cgi/doi/10.1136/bmj.b4336

High salt intake is associated with significantly greater risk of both stroke and cardiovascular disease, concludes a study published on bmj.com today.

The link between high salt intake and high blood pressure is well established, and it has been suggested that a population-wide reduction in dietary salt intake has the potential to substantially reduce the levels of cardiovascular disease.

The World Health Organization recommended level of salt consumption is 5 g (about one teaspoon) per day at the population level, yet dietary salt intake in most Western countries is close to 10g per day (and much higher in many Eastern European countries).

Collaborative research conducted by Professor Pasquale Strazzullo at the University of Naples, Italy and Professor Francesco Cappuccio at the University of Warwick, UK analysed the results of 13 published studies involving over 170,000 people that directly assessed the relationship between levels of habitual salt intake and rates of stroke and cardiovascular disease.

Differences in study design and quality were taken into account to minimise bias.

Their analysis shows unequivocally that a difference of 5 g a day in habitual salt intake is associated with a 23% difference in the rate of stroke and a 17% difference in the rate of total cardiovascular disease.

Based on these results, the authors estimate that reducing daily salt intake by 5 g at the population level could avert one and a quarter million deaths from stroke and almost three million deaths from cardiovascular disease each year. Furthermore, because of imprecision in measurement of salt intake, these effect sizes are likely to be underestimated, say the authors.

These results support the role of a substantial population reduction in salt intake for the prevention of cardiovascular disease, they conclude.

This study is a useful and welcome addition to the medical literature, and strengthens the case for population-wide salt reduction, says Professor Lawrence Appel from Johns Hopkins University, in an accompanying editorial.

Contacts:
Research: Pasquale Strazzullo, Professor of Medicine, Department of Clinical and Experimental Medicine, "Federico II" ESH Excellence Centre of Hypertension, University of Naples Medical School, Naples, Italy
Email: strazzul@unina.it

Editorial: Lawrence Appel, Professor of Medicine (via Stephanie Desmon, Senior Media Relations Representative), Johns Hopkins University, Baltimore, MD, USA
Email: sdesmon1@jhmi.edu

Friday, June 26, 2009

Tobacco, Public Health, and the FDA

Moral of the story: The FDA and local governments can now finally treat tobacco as the addictive substance that it is, protecting the health of Americans and decreasing costs ($96B).

Tobacco, Public Health, and the FDA
Gregory D. Curfman, M.D., Stephen Morrissey, Ph.D., and Jeffrey M. Drazen, M.D.
Published at www.nejm.org June 22, 2009 (10.1056/NEJMe0905622)

More than a decade ago, David Kessler, then Commissioner of the Food and Drug Administration (FDA), launched a bold initiative to regulate tobacco. He believed that since nicotine is an addictive substance, it fell under the statutory authority of the FDA to regulate it as a drug and cigarettes as the delivery vehicle.
His effort failed, however, when the U.S. Supreme Court decided in a 5-to-4 ruling (FDA v. Brown & Williamson Tobacco Corp.) that the Food, Drug, and Cosmetic Act of 1938, which defined the FDA's authority, did not grant the agency jurisdiction to regulate tobacco. Writing for the Court, Justice Sandra Day O'Connor concluded that "it is plain that Congress has not given the FDA the authority to regulate tobacco products."1 The Court's decision was based on its reading of the statutory language in the act, not on what was best for the health of the public.
Today, President Barack Obama changed all that. With the signing of the Family Smoking Prevention and Tobacco Control Act of 2009, which was passed by sizable majorities in both the House and the Senate (and which we endorsed), the FDA has been given broad authority to regulate tobacco products. We believe that this historic legislation can have an unparalleled positive impact on the health of the American public.
The act establishes the Center for Tobacco Products, a unit within the FDA that will be funded by user fees from tobacco manufacturers and importers — $235 million in fiscal year 2010, rising to $712 million over the next 10 years. The center is charged with regulating tobacco products for the explicit purpose of protecting the health of the public. The FDA will now have the authority to require that all ingredients, compounds, and additives in tobacco products be reported to the agency, and those found to have harmful health effects may be banned. Nicotine levels in cigarettes may be regulated, but neither nicotine nor cigarettes may be banned outright. In keeping with the act's focus on protecting those under 18 years of age, flavorings in cigarettes, which are meant to appeal to young smokers, are banned, with the exception of menthol, which could be banned later if found to be a health hazard. No new tobacco product can be marketed unless first approved by the FDA.
Importantly, the act will also allow regulation of so-called modified risk tobacco products, which are typically identified by terms on the package such as "light," "low," or "mild." The use of such terms will no longer be permitted unless the product has been shown to significantly reduce harm. Warning labels on cigarette packages will be made more graphic and will require the use of color. Tobacco companies may no longer sponsor sporting events.
For the first time in almost 40 years, state and local governments will be allowed to regulate the marketing of tobacco, establishing restrictions that may be more rigorous than those of the FDA. In addition, the act requires that the 1996 Tobacco Rule, which was put in place by Commissioner Kessler and deemed unconstitutional by the Supreme Court, must be reinstated. This rule places restrictions on tobacco advertising, including a ban on outdoor advertising within 1000 ft of a school. It is anticipated that this regulation may be the focus of a constitutional challenge on the basis that such advertising represents commercial speech subject to First Amendment protection. Still, there is good reason to believe that this carefully crafted provision, which is narrowly tailored to focus on smoking prevention in the nation's young, will survive any such legal challenge.
The long-term impact of the Family Smoking Prevention and Tobacco Control Act on the health of the public will depend critically on its implementation through strict regulations, rigorously enforced. FDA Commissioner Margaret Hamburg and Principal Deputy Commissioner Joshua Sharfstein promise to be strong advocates for rigorous enforcement.
In a recent article in the Journal, Hamburg and Sharfstein laid out their new mission.2 They regard the FDA as a public health agency whose purpose is not just to regulate the nation's food and drug supplies, but to protect the health of American citizens. Hamburg has also indicated that she is eager to undertake the regulation of tobacco and said in an interview, "We now have an opportunity to really make a difference with what is probably the No. 1 public health concern in the nation and the world."3
Few threats to the health of the public are as onerous as tobacco. Each year more than 435,000 Americans die of tobacco-related illnesses, principally heart, vascular, and lung diseases. Tobacco use is also associated with substantial morbidity and diminished quality of life. More than one in five Americans still smoke, an astonishing figure given the overwhelming evidence of harm. In addition to excess morbidity and mortality, tobacco adds considerably to health care costs at a time when reducing costs is a national priority. The total annual health care expenditures caused by smoking run to $96 billion.4 Along with other critical prevention goals, such as controlling obesity and increasing levels of physical activity, the elimination of cigarette smoking is central to improving the health of our citizens and mitigating the growth of health care costs.
The Family Smoking Prevention and Tobacco Control Act of 2009 comes at a propitious moment in U.S. history. We strongly support the FDA's new leaders and urge them to implement the act aggressively. As a medical journal, we are committed to eliminating the public health threat tobacco represents to American society and the world.
Source Information
This article (10.1056/NEJMe0905622) was published on June 22, 2009, at NEJM.org.
References

FDA v. Brown & Williamson Tobacco Corp. 529 U.S. 120 (2000).
Hamburg MA, Sharfstein JM. The FDA as a public health agency. N Engl J Med 2009;360:2493-2495. [Free Full Text]
Harris G. New F.D.A. chief says she'll toughen enforcement efforts. New York Times. June 17, 2009:A19.
Campaign for Tobacco-free Kids. Toll of tobacco in the United States of America. April 2009. (Accessed June 22, 2009, at http://www.tobaccofreekids.org/research/factsheets/pdf/0072.pdf.)

Monday, June 15, 2009

Alcohol’s Good for You? Some Scientists Doubt It

Moral of the story- Correlation is not causation. Writing from Guatemala there is little time to expand upon this excellent story, but read it! You may change your mind about "needing" that glass of wine and instead go for a walk or run.

http://www.nytimes.com/2009/06/16/health/16alco.html?ref=health

From the New York Times-
Published: June 15, 2009

By now, it is a familiar litany. Study after study suggests that alcohol in moderation may promote heart health and even ward off diabetes and dementia. The evidence is so plentiful that some experts consider moderate drinking — about one drink a day for women, about two for men — a central component of a healthy lifestyle.

But what if it’s all a big mistake?

For some scientists, the question will not go away. No study, these critics say, has ever proved a causal relationship between moderate drinking and lower risk of death — only that the two often go together. It may be that moderate drinking is just something healthy people tend to do, not something that makes people healthy.

“The moderate drinkers tend to do everything right — they exercise, they don’t smoke, they eat right and they drink moderately,” said Kaye Middleton Fillmore, a retired sociologist from the University of California, San Francisco, who has criticized the research. “It’s very hard to disentangle all of that, and that’s a real problem.”

Some researchers say they are haunted by the mistakes made in studies about hormone replacement therapy, which was widely prescribed for years on the basis of observational studies similar to the kind done on alcohol. Questions have also been raised about the financial relationships that have sprung up between the alcoholic beverage industry and many academic centers, which have accepted industry money to pay for research, train students and promote their findings.

“The bottom line is there has not been a single study done on moderate alcohol consumption and mortality outcomes that is a ‘gold standard’ kind of study — the kind of randomized controlled clinical trial that we would be required to have in order to approve a new pharmaceutical agent in this country,” said Dr. Tim Naimi, an epidemiologist with the Centers for Disease Control and Prevention.

Even avid supporters of moderate drinking temper their recommendations with warnings about the dangers of alcohol, which has been tied to breast cancer and can lead to accidents even when consumed in small amounts, and is linked with liver disease, cancers, heart damage and strokes when consumed in larger amounts.

“It’s very difficult to form a single-bullet message because one size doesn’t fit all here, and the public health message has to be very conservative,” said Dr. Arthur L. Klatsky, a cardiologist in Oakland, Calif., who wrote a landmark study in the early 1970s finding that members of the Kaiser Permanente health care plan who drank in moderation were less likely to be hospitalized for heart attacks than abstainers. (He has since received research grants financed by an alcohol industry foundation, though he notes that at least one of his studies found that alcohol increased the risk of hypertension.)

“People who would not be able to stop at one to two drinks a day shouldn’t drink, and people with liver disease shouldn’t drink,” Dr. Klatsky said. On the other hand, “the man in his 50s or 60s who has a heart attack and decides to go clean and gives up his glass of wine at night — that person is better off being a moderate drinker.”

Health organizations have phrased their recommendations gingerly. The American Heart Association says people should not start drinking to protect themselves from heart disease. The 2005 United States dietary guidelines say that “alcohol may have beneficial effects when consumed in moderation.”

The association was first made in the early 20th century. In 1924, a Johns Hopkins biologist, Raymond Pearl, published a graph with a U-shaped curve, its tall strands on either side representing the higher death rates of heavy drinkers and nondrinkers; in the middle were moderate drinkers, with the lowest rates. Dozens of other observational studies have replicated the findings, particularly with respect to heart disease.

“With the exception of smoking and lung cancer, this is probably the most established association in the field of nutrition,” said Eric Rimm, an associate professor of epidemiology and nutrition at the Harvard School of Public Health. “There are probably at least 100 studies by now, and the number grows on a monthly basis. That’s what makes it so unique.”

Alcohol is believed to reduce coronary disease because it has been found to increase the “good” HDL cholesterol and have anticlotting effects. Other benefits have been suggested, too. A small study in China found that cognitively impaired elderly patients who drank in moderation did not deteriorate as quickly as abstainers. A report from the Framingham Offspring Study found that moderate drinkers had greater mineral density in their hipbones than nondrinkers. Researchers have reported that light drinkers are less likely than abstainers to develop diabetes, and that those with Type 2 diabetes who drink lightly are less likely to develop coronary heart disease.

But the studies comparing moderate drinkers with abstainers have come under fire in recent years. Critics ask: Who are these abstainers? Why do they avoid alcohol? Is there something that makes them more susceptible to heart disease?

Some researchers suspect the abstainer group may include “sick quitters,” people who stopped drinking because they already had heart disease. People also tend to cut down on drinking as they age, which would make the average abstainer older — and presumably more susceptible to disease — than the average light drinker.

In 2006, shortly after Dr. Fillmore and her colleagues published a critical analysis saying a vast majority of the alcohol studies they reviewed were flawed, Dr. R. Curtis Ellison, a Boston University physician who has championed the benefits of alcohol, hosted a conference on the subject. A summary of the conference, published a year later, said scientists had reached a “consensus” that moderate drinking “has been shown to have predominantly beneficial effects on health.”

The meeting, like much of Dr. Ellison’s work, was partly financed by industry grants. And the summary was written by him and Marjana Martinic, a senior vice president for the International Center for Alcohol Policies, a nonprofit group supported by the industry. The center paid for tens of thousands of copies of the summary, which were included as free inserts in two medical journals, The American Journal of Medicine and The American Journal of Cardiology.

In an interview, Dr. Ellison said his relationship with the industry did not influence his work, adding, “No one would look at our critiques if we didn’t present a balanced view.”

Dr. Fillmore and the co-authors of her analysis posted an online commentary saying the summary had glossed over some of the deep divisions that polarized the debate at the conference. “We also dispute Ellison and Martinic’s conclusions that more frequent drinking is the strongest predictor of health benefits,” they wrote.

(Dr. Fillmore has received support from the Alcohol Education and Rehabilitation Foundation of Australia, a nonprofit group that works to prevent alcohol and substance abuse.)

Dr. Ellison said Dr. Fillmore’s analysis ignored newer studies that corrected the methodological errors of earlier work. “She threw out the baby with the bathwater,” he said.

Meanwhile, two central questions remain unresolved: whether abstainers and moderate drinkers are fundamentally different and, if so, whether it is those differences that make them live longer, rather than their alcohol consumption.

Dr. Naimi of the C.D.C., who did a study looking at the characteristics of moderate drinkers and abstainers, says the two groups are so different that they simply cannot be compared. Moderate drinkers are healthier, wealthier and more educated, and they get better health care, even though they are more likely to smoke. They are even more likely to have all of their teeth, a marker of well-being.

“Moderate drinkers tend to be socially advantaged in ways that have nothing to do with their drinking,” Dr. Naimi said. “These two groups are apples and oranges.” And simply advising the nondrinkers to drink won’t change that, he said.

Some scientists say the time has come to do a large, long-term randomized controlled clinical trial, like the ones for new drugs. One approach might be to recruit a large group of abstainers who would be randomly assigned either to get a daily dose of alcohol or not, and then closely followed for several years; another might be to recruit people who are at risk for coronary disease.

But even the experts who believe in the health benefits of alcohol say this is an implausible idea. Large randomized trials are expensive, and they might lack credibility unless they were financed by the government, which is unlikely to take on the controversy. And there are practical and ethical problems in giving alcohol to abstainers without making them aware of it and without contributing to accidents.

Still, some small clinical trials are already under way to see whether diabetics can reduce their risk of heart disease by consuming alcohol. In Boston, researchers at Beth Israel Deaconess Medical Center are recruiting volunteers 55 and over who are at risk for heart disease and randomly assigning them to either drink plain lemonade or lemonade spiked with tasteless grain alcohol, while scientists track their cholesterol levels and scan their arteries.

In Israel, researchers gave people with Type 2 diabetes either wine or nonalcoholic beer, finding that the wine drinkers had significant drops in blood sugar, though only after fasting; the Israeli scientists are now working with an international team to begin a larger two-year trial.

“The last thing we want to do as researchers and physicians is expose people to something that might harm them, and it’s that fear that has prevented us from doing a trial,” said Dr. Sei Lee of the University of California, San Francisco, who recently proposed a large trial on alcohol and health.

“But this is a really important question,” he continued. “Because here we have a readily available and widely used substance that may actually have a significant health benefit — but we just don’t know enough to make recommendations.”

Tuesday, May 12, 2009

One Fish, Two Fish, Fish You Want to Buy, Fish You Never Want to Die

Moral of the story: We all know we are supposed to eat more fish. It is a diet rich is omega-3 fatty acids and low in more harmful fats. Yet at the same time we are constantly reminded of the terrible overfishing going on around the world. This website will help you select the most eco-friendly fish to help keep you healthy.

http://www.edf.org/page.cfm?tagID=1521

The website is easy to use, has recipes and health information along with lists of what fish to eat and which ones to avoid. Highly recommended.

Thursday, April 16, 2009

heart-health benefits from a Mediterranean diet

Moral of the story: Time and again the Mediterranean diet is proven to be a healthy eating option. This meta-analysis (aggregates all the previous studies) finalizes the debate, if there ever was one. Time to break out the fish and olives, but remember to eat sustainably, we want everyone to be able to enjoy these health benefits many years from now.

Heartwire: Prevention
Meta-analysis supports heart-health benefits from a Mediterranean diet
April 16, 2009 | Marlene Busko

Hamilton, ON - Strong evidence supports the protective effect of a Mediterranean diet on risk of CHD, and overall diet pattern appears more important than individual foods [1].

These findings, from a review of close to 200 studies, are published in the April 13, 2009 issue of the Archives of Internal Medicine.

"We found strong evidence that a 'Western' diet—which is high in processed meats, red meats, butter, eggs, refined grains, and high-fat dairy products—is associated with an increased risk of CAD, so we could say [to patients]: 'You should consume less of those types of foods and gravitate more toward a "prudent" diet or a Mediterranean diet, which are both high in fruits and vegetables, legumes, whole grains, and fish,' " senior author Dr Sonia Anand (McMaster University, Hamilton, ON) told heartwire.

Although this message is not really new, what is new is the way that this review assessed the strength of the evidence, she noted.

The study also found strong evidence of increased CHD risk from consuming trans-fatty acids and foods with a high glycemic index such as white potatoes, sugar, white rice, and white bread.

Physicians should advise patients: "Lower your trans-fats, lower your saturated fats, but also watch for some of these simple carbohydrates, because they can have adverse effects as well,'' said Anand.


Diet dilemma

The relationship between diet and CHD has been studied for decades, yet there is still some confusion about which foods or diets are best, since cohort studies and randomized controlled trials have often produced discrepant results, the researchers write.

To examine the strength of the evidence supporting a causal link between diet and CHD, the researchers reviewed 146 prospective cohort studies and 43 randomized controlled trials (RCTs).

Studies were scored on how well they met four criteria of strength, consistency, temporality, and coherence. A score of 4 was considered strong evidence of a cause-and-effect relationship between dietary exposure and disease.


Dietary pattern vs single food

In the cohort studies, a Mediterranean diet—characterized by higher intake of vegetables, legumes, fruits, nuts, whole grains, cheese or yogurt, fish, and monounsaturated as opposed to saturated fatty acids—and a "prudent diet"—characterized by high intake of vegetables, fruit, legumes, whole grains, fish, and other seafood—were each associated with significantly lower risk of CHD. Similarly, strong evidence supported the benefits from monounsaturated fatty acids and foods such as vegetables and nuts and the harm from trans-fatty acids and foods with a high glycemic index.

In the RCTs, however, only the Mediterranean diet was strongly linked to risk of CHD.

"Our findings support the strategy of investigating dietary patterns in cohort studies and RCTs for common and chronic complex diseases such as CHD," the researchers write.


Study reinforces heart-healthy diet

Commenting on the results for heartwire, Dr Robert Eckel (University of Colorado, Denver) said that the study confirms previous notions about what a heart-healthy diet is all about.

It's not a matter of good foods and bad foods. It's what the overall quality of the diet is.

"I think cardiologists need to increasingly make lifestyle-related issues an important part of their practice," he added. "This is another article reinforcing that a heart-healthy diet contains certain constituents and avoids certain constituents."

Concurring with the study authors, he noted: "Overall, the dietary pattern is what needs to be emphasized. It's not a matter of good foods and bad foods. It's what the overall quality of the diet is. The Western pattern is high in saturated fat, trans-fat, and cholesterol, whereas a Mediterranean diet and 'prudent' diet include more monounsaturated or polyunsaturated fats, and there is more fish consumption."

No financial disclosures were reported.
Source
  1. Mente A, de Koning L, Shannon HS, et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009; 169:659-669.

Monday, March 23, 2009

Large meta-analysis links anger, hostility with CHD risk, particularly in men

Moral of the story: Take 10 deep breaths before you get angry, your heart will thank you later.

Heartwire - Prevention
Large meta-analysis links anger, hostility with CHD risk, particularly in men
March 10, 2009 | Deborah Wormser

London, UK - Anger and hostility were associated with a 19% increase in coronary heart disease (CHD) events in healthy individuals and a 24% increase in risk among those with preexisting CHD, researchers report in the first large, systematic meta-analysis to show significant links between those two mind states and CHD [1].

"The harmful effect of anger and hostility has been widely asserted, but previous reviews have been inconclusive," Dr Yoichi Chida and Dr Andrew Steptoe (both from University College London, UK) write in their review published in the March 17, 2009 issue of the Journal of the American College of Cardiology.

"Intriguingly, the harmful effect of anger and hostility on CHD events in the healthy populations was greater in men than women," the researchers write. In the healthy-population studies, the researchers found a strong association between anger and hostility and CHD in men (HR 1.22, p<0.001),>

"Previous meta-analyses failed to show significant associations of anger and hostility with CHD," Chida told heartwire. Chida added that this report includes several studies published since the last major meta-analytical review.

Chida's review included 21 articles (71 606 individuals) on CHD outcomes in healthy populations and 18 articles (n=8120) of people with preexisting CHD, from studies conducted in Australasia, Europe, and America. Anger and hostility were associated with increased CHD events in the healthy-population studies, with a combined HR of 1.19 (p=0.008), and those emotions were associated with poor prognosis in the population with existing CHD (HR 1.24, p=0.002). In the studies of individuals with baseline CHD, the poor prognosis associated with anger and hostility persisted after researchers fully controlled for basal disease status and treatment, the article states.

Although the body of research investigating the association between anger and hostility and CHD has grown during the past 25 years, several reviews of the literature have produced different findings, possibly because some looked at individual facets of the overall construct, such as hostility alone. Another possible confounder could be the inclusion of cross-sectional, retrospective, and prospective studies in previous reviews, the researchers write in their analysis, which was limited to prospective cohort investigations.

The analysis found that CHD risk appeared to be mediated through high-risk behaviors, with the association between anger/hostility and CHD becoming no longer significant after full adjustment for behavioral factors such as smoking, physical activity, body-mass index, or socioeconomic status.


Small but notable risk

In an accompanying editorial [2], Dr Johan Denollet and Dr Susanne S Pedersen (both from Tilburg University, the Netherlands) point out that while the overall size of the associations between anger and hostility and subsequent CHD reported by Chida et al might seem small, it appears notable when compared with the 11% increased risk associated with von Willebrand factor in the Reykjavik Study [3].

"This meta-analytic review is of high scientific quality and provides us with a reliable estimate of the risk associated with anger/hostility," Denollet told heartwire. "This review has important clinical implications, because it supports the notion that adverse psychological factors do matter in the development and progression of CHD. Moreover, these findings indicate that psychological factors, in this case anger/hostility, start to show their adverse effect after a couple of years, suggesting that these factors are especially of importance in the long run and that more long-term follow-up studies are needed."

Symptoms of anger/hostility should be taken seriously. "Clinicians may consider referring their coronary patients with high levels of anger for behavioral intervention," he said in the interview with heartwire.

Regarding the findings that the association between anger/hostility and CHD appears mediated by lifestyle behaviors and socioeconomic status, Denollet told heartwire, "I think that a number of these unhealthy lifestyles—smoking, overeating—may reflect attempts to downregulate feelings of tension associated with anger/hostility. Socioeconomic status may reflect a vulnerability factor for increased levels of anger/hostility."

One important direction for future research would be the role of emotion-regulation strategies that might moderate the effects of anger and hostility.

"There is some evidence that suppression of anger increases the risk of hypertension and coronary disease and that inhibition of emotion and behavior in general may further increase the risk of stress-related CHD. Future research should more often focus on the interplay between negative emotions and emotion-regulation strategies as a determinant of major coronary events," Denollet said.

"I think we need to be careful to not simply conclude that 'anger is bad for the heart.' After all, anger is a natural emotion that can be very adaptive (eg, as a warning signal), provided that this negative emotion is regulated and used in a socially meaningful and adaptive way," he added.

Chida receives support from the Kanae Foundation for the Promotion of Medical Science and the Medical Research Council. Steptoe receives support from the British Heart Foundation. Denollet and Pedersen report no disclosures.
Sources
  1. Chida Y, Steptoe A. The association of anger and hostility with future Coronary Heart Disease. J Am Coll Cardiol 2009; 53:936-946. DOI:10.1016/j.jacc.2008.11.044.
  2. Denollet J, Pedersen SS. Anger, depression, and anxiety in cardiac patients. J Am Coll Cardiol 2009; 53:947-9.
  3. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Engl J Med 2004; 350:1387-97.

Very low LDL and normal BP result in slowest progression of atherosclerosis

Moral of the story: 2 thing - Blood Pressure, LDL. Worry about those two things. Get them back to normal and you will go a long way towards preventing heart disease.

Heartwire - Clinical cardiology
Very low LDL and normal BP result in slowest progression of atherosclerosis
March 23, 2009 | Michael O'Riordan

Cleveland, OH - Patients with coronary artery disease (CAD) who reduce LDL cholesterol to very low levels and achieve a normal systolic blood pressure have the slowest progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS), a new study has shown [1]. The findings, according to investigators, support the need for intensive management of global risk in patients with CAD.

"What's happened in recent years with the advent of more potent statins and all the education done around that is that getting people to LDL goal is achieved fairly well," senior investigator Dr Steven Nissen (Cleveland Clinic, OH) told heartwire. "But getting people to dual goals is not done well around the country. We wanted to tell people that there really is some pretty good evidence here that if you get your blood pressure down to normal and your LDL down below 70, this is a disease that can not only be halted, but potentially can even regress."

The results of the study are published in the March 24, 2009 issue of the Journal of the American College of Cardiology.


Seven studies rolled into one

To clarify the relationship between LDL cholesterol and systolic blood pressure and their effects on coronary plaque progression, the researchers, led by Dr Adnan Chhatriwalla (Cleveland Clinic) studied 3437 patients with established CAD enrolled in seven clinical trials. The studies included REVERSAL, CAMELOT, ACTIVATE, ASTEROID, ILLUSTRATE, PERISCOPE, and STRADIVARIUS, a group of trials that investigated statins, acyl coenzyme A:cholesterol acyltransferase (ACAT) and cholesteryl ester transfer protein (CETP) inhibitors, rimonabant, ACE inhibitors, and calcium-channel blockers, among others.

Patients were stratified into four groups based on their average on-treatment LDL-cholesterol levels and systolic blood pressure:

  • LDL cholesterol <70 mg/dL and systolic blood pressure <120 mm Hg.
  • LDL cholesterol <70 mg/dL and systolic blood pressure >120 mm Hg.
  • LDL cholesterol >70 mg/dL and systolic blood pressure <120 mm Hg.
  • LDL cholesterol >70 mg/dL and systolic blood pressure >120 mmHg.

Changes in atheroma burden were monitored by IVUS, which was measured at baseline and at 18 to 24 months.

Patients with very low LDL-cholesterol levels and normal systolic blood pressure, group 1, had the least progression in percent atheroma volume (PAV) and total atheroma volume (TAV). In addition, these patients also had less frequent atheroma progression and more frequent regression. In patients with systolic blood pressure >120 mm Hg who still had very low LDL cholesterol levels, group 2, less progression of PAV and TAV was also observed.

"It really makes a big difference if you can get both down," said Nissen. "It's a big payoff for patients if physicians are diligent about getting LDL and blood pressure under control."

Among patients with LDL-cholesterol levels >70 mg/dL, normal systolic blood pressure was associated with no greater reduction in PAV or TAV, suggesting that lipid lowering has a larger impact than blood-pressure control on plaque progression, findings supported by recent clinical trials.

The findings challenge current treatment recommendations for hypertension, noted Nissen, and he recommends treating prehypertensive patients with coronary disease, those with pressures of 120 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic. In the CAMELOT study, he points out, the calcium-channel blocker amlodipine decreased the risk of cardiovascular events in patients with CAD and normal blood pressure, as did the ACE inhibitor enalapril, but to a lesser extent.

"Remember that these are all people who have coronary artery disease," said Nissen. "These are not your typical primary-prevention patients with hypertension. They already have atherosclerotic disease in their coronaries. We think the evidence is pretty strong that if you already have plaques in your coronaries, you really to have a lower blood-pressure target. . . . Our IVUS data suggest that there is opportunity here to help patients."

Nissen admitted that the issue needs to be studied further and that the ongoing AQUARIUS study will assess changes in atherosclerotic disease progression with aliskiren (Tekturna, Novartis) when given in addition to standard therapy in CAD patients with prehypertension.


More data still needed

In an editorial accompanying the published study, Drs Jonathan Tobis and Alice Perlowski (University of California, Los Angeles) write that human and animal data make clear that a combination of aggressive lipid and blood-pressure control are necessary for a maximum attenuation of plaque progression, improved endothelial function, and reduced inflammation caused by oxidative stress [2].

Regarding the treatment of prehypertensive patients, Tobis and Perlowski write that a lack of data has contributed to a delayed acceptance of the need for drug therapy. In addition to AQUARIUS, the ongoing SPRINT, which is comparing intensive blood-pressure control (<120>130 mm Hg who have one additional risk factor, will help answer those questions.

The editorialists note that plaque progression/regression on IVUS is helpful in determining whether or not clinicians are helping their patients, but hard clinical end points are still needed, especially as they are shown to correspond with predictions based on the IVUS surrogates. Until then, "conclusions derived from these trials should be considered inferential, to be used as guides for future trials focused on clinical-outcomes measures," they write.

Asked about the polypill, Nissen told heartwire that he was not an initial fan, but with these and other data, he is starting to warm up to it. "The idea of having something that you go and get for $10 for three months that would control your blood pressure and your lipids, this study makes the case that it might make some sense."

New results about a polypill approach for primary prevention, combining a BP-lowering drug, a statin, and aspirin in a single pill, will be presented at the American College of Cardiology 2009 meeting next week.

Nissen reports receiving research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis and that he donates honoraria, consulting fees, and other payments directly to charity. Chhattriwalla reports no conflicts.
Sources
  1. Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009; 53: 1110-1115.
  2. Tobis JM, Perlowski A. Atheroma volume by intravascular ultrasound as a surrogate for clinical endpoints. J Am Coll Cardiol 2009; 53: 1116-1118.

Meat Intake and Mortality

Moral of the story: Reducing meat consumption may not be a bad idea. You do not necessarily have to eliminate it from your diet, but maybe you shouldn't have filet mignon 7 days a week. The study shows that those people eating the most red and processed meat were more likely to die than those eating the least amount of red and processed meat. Causes of mortality were cancer and cardiovascular related. This is a gigantic study so trust the results.

Meat Intake and Mortality

A Prospective Study of Over Half a Million People

Rashmi Sinha, PhD; Amanda J. Cross, PhD; Barry I. Graubard, PhD; Michael F. Leitzmann, MD, DrPH; Arthur Schatzkin, MD, DrPH

Arch Intern Med. 2009;169(6):562-571.

Background High intakes of red or processed meat may increase the risk of mortality. Our objective was to determine the relations of red, white, and processed meat intakes to risk for total and cause-specific mortality.

Methods The study population included the National Institutes of Health–AARP (formerly known as the American Association of Retired Persons) Diet and Health Study cohort of half a million people aged 50 to 71 years at baseline. Meat intake was estimated from a food frequency questionnaire administered at baseline. Cox proportional hazards regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) within quintiles of meat intake. The covariates included in the models were age, education, marital status, family history of cancer (yes/no) (cancer mortality only), race, body mass index, 31-level smoking history, physical activity, energy intake, alcohol intake, vitamin supplement use, fruit consumption, vegetable consumption, and menopausal hormone therapy among women. Main outcome measures included total mortality and deaths due to cancer, cardiovascular disease, injuries and sudden deaths, and all other causes.

Results There were 47 976 male deaths and 23 276 female deaths during 10 years of follow-up. Men and women in the highest vs lowest quintile of red (HR, 1.31 [95% CI, 1.27-1.35], and HR, 1.36 [95% CI, 1.30-1.43], respectively) and processed meat (HR, 1.16 [95% CI, 1.12-1.20], and HR, 1.25 [95% CI, 1.20-1.31], respectively) intakes had elevated risks for overall mortality. Regarding cause-specific mortality, men and women had elevated risks for cancer mortality for red (HR, 1.22 [95% CI, 1.16-1.29], and HR, 1.20 [95% CI, 1.12-1.30], respectively) and processed meat (HR, 1.12 [95% CI, 1.06-1.19], and HR, 1.11 [95% CI 1.04-1.19], respectively) intakes. Furthermore, cardiovascular disease risk was elevated for men and women in the highest quintile of red (HR, 1.27 [95% CI, 1.20-1.35], and HR, 1.50 [95% CI, 1.37-1.65], respectively) and processed meat (HR, 1.09 [95% CI, 1.03-1.15], and HR, 1.38 [95% CI, 1.26-1.51], respectively) intakes. When comparing the highest with the lowest quintile of white meat intake, there was an inverse association for total mortality and cancer mortality, as well as all other deaths for both men and women.

Conclusion Red and processed meat intakes were associated with modest increases in total mortality, cancer mortality, and cardiovascular disease mortality.


Author Affiliations: Nutritional Epidemiology Branch (Drs Sinha, Cross, Leitzmann, and Schatzkin) and Biostatistics Branch (Dr Graubard), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland.

Thursday, March 19, 2009

Task force revises aspirin guidelines for heart attack, stroke

Moral of the story: Men between 45 and 79 should likely be taking asprin while women between 55 and 79 should likely be taking apsrin to prevent stroke. Talk to your physician about risk of GI bleeding. Thousands of lives could be saved by following these guidelines.

Task force revises aspirin guidelines for heart attack, stroke

Cardiovascular Business
Wednesday March 18, 2009

The U.S. Preventive Services Task Force has recommended aspirin use for primary prevention of heart attack and stroke in the March 17 issue of the Annals of Internal Medicine, citing its improved specificity over previous guidelines.

The task force found that men between the ages of 45 and 79 should use aspirin to reduce their risk for heart attacks when the benefits outweigh the harms for potential gastrointestinal bleeding. Women between the ages of 55 and 79 should use aspirin to reduce their risk for ischemic stroke when the benefits outweigh the harms for potential gastrointestinal bleeding.

However, the task force was against the use of aspirin for stroke prevention in women younger than 55 years and for MI prevention in men younger than 45 years.

"The task force has taken positive steps to lend clarity to patients and physicians about the value of aspirin for prevention of cardiovascular events," said American College of Preventive Medicine (ACPM) President Mark B. Johnson, MD. "The new guidelines make it clear that physicians, as a matter of routine practice, should be discussing the pros and cons of daily aspirin use with patients in the target groups."

An ACPM-sponsored survey published in the May 2007 edition of the American Journal of Preventive Medicine found a conversation between the patient and physician to be the strongest predictor of appropriate aspirin use, and that only about one in three patients who are at high risk are actually taking daily aspirin. A separate study by the Partnership for Prevention found that 45,000 lives could be saved each year if 90 percent of the target population took a low-dose aspirin every day. The studies led the American Medical Association (AMA) to adopt a policy to increase education among physicians on the importance of appropriate aspirin counseling.

With the release, the UPSTF updates its aspirin recommendations from 2002, which called on clinicians to discuss aspirin use for primary prevention with adults who are at increased risk for cardiovascular disease. The new USPSTF findings actually recommend aspirin use where benefits outweigh the harms, and further define the appropriate age and gender groupings for which aspirin is indicated.

"We think the new guidelines provide another tool in the armamentarium of the physician and the patient for assuring that a discussion about cardiovascular risk and potential aspirin use routinely takes place in the clinical setting," said David Shih, MD, senior director of medical affairs at ACPM.
Last Updated ( Thursday, March 19 2009 )

Wednesday, March 18, 2009

Metabolic disorders linked to cognitive decline

Moral of the story: Manage your chronic diseases! Stay on top of treatment, exercise and see your doctor. The last thing you want on top of diabetes is Alzheimer's disease.

Metabolic disorders linked to cognitive decline
March 17, 2009 Allison Gandey
Edited from Medscape Medical News—a professional news service of WebMD

New York, NY and Seattle, WA - Evidence is mounting that metabolic and neurological diseases share common risk factors, according to two studies in the March 2009 issue of the Archives of Neurology.
"Preventing heart disease, stroke, and diabetes—or making sure these conditions are well managed in patients diagnosed with them—can potentially slow the disease progression of Alzheimer's," senior author on one of the studies, Dr Yaakov Stern (Columbia University, New York), said in a news release. Stern et al, led by Dr Elizabeth Helzner (Columbia University) hypothesized that vascular factors such as heart disease, stroke, diabetes, hypertension, smoking, and blood lipid levels may predict the progression of Alzheimer's disease [1]. The group studied 156 patients followed for a mean of 3.5 years. Participants were from the Washington Heights and Inwood Columbia Aging Project, a multiethnic, community-based, prospective study of aging in northern Manhattan.
Researchers found that patients with a history of diabetes and elevated levels of cholesterol, especially LDL cholesterol, had faster cognitive decline. In fact, each 10-U increase in cholesterol and LDL cholesterol was associated with a 0.10-standard-deviation decrease in cognitive score per year of follow-up (p<0.001 for total cholesterol; p=0.001 for LDL cholesterol).
Investigators found that a history of heart disease and stroke were associated with cognitive decline only in carriers of the APOE e4 allele.
"These findings indicate that controlling vascular conditions may be one way to delay the course of Alzheimer's, which would be a major development in the treatment of this devastating disease," Stern said.Fluctuations in weight may boost dementia risk
In the second study published in the same issue of the Archives of Neurology, investigators show that obese middle-aged adults and underweight elderly people have an increased dementia risk [2].
Using data from the Cardiovascular Health Study, researchers studied the body-mass index (BMI) of participants at mid- and late life. Patients were from a community-dwelling sample at four US sites.
Investigators included 2798 people. Of these, 480 had incident dementia, 245 had Alzheimer's disease, and 213 had vascular dementia.
They found that middle-aged patients who were obese had an increased risk for dementia (BMI >30 vs normal-weight BMI 20 to 25), adjusted for demographics (hazard ratio 1.39; 95% CI 1.03-1.87), although this observation was weakened after adjustment for cardiovascular risk factors (hazard ratio 1.36; 95% CI 0.94-1.95).
These results help explain the 'obesity paradox.'
But the risk estimates were reversed in assessments of late-life BMI. Underweight people, those with a BMI of less than 20, had an increased risk for dementia (hazard ratio 1.62; 95% CI 1.02-2.64). Surprisingly, being overweight later in life was not associated with an increased risk (hazard ratio 0.92; 95% CI 0.72-1.18), and being obese reduced the risk for dementia (hazard ratio 0.63; 95% CI 0.44-0.91).
"These results help explain the 'obesity paradox,' " the researchers, led by Dr Annette Fitzpatrick (University of Washington, Seattle), write. "Differences in dementia risk across time are consistent with physical changes in the trajectory toward disability."
These findings suggest that the predictive ability of BMI changes across time, they note
"Weight loss occurs with comorbidities at older ages and is often reflective of poor health," write Fitzpatrick and her team. "Weight loss, along with psychological, behavioral, and mobility problems, is one of the principal manifestations of Alzheimer's disease. Weight loss may predate dementia onset by as much as 10 years."
The researchers conclude: "These results reinforce the necessity of monitoring weight loss closely in older adults."
The complete contents of Medscape Medical News, a professional news service of WebMD, can be found at www.medscape.com, a website for medical professionals.
Sources
Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66:343-348.
Fitzpatrick AL, Kuller LH, Lopez OL, Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66:336-342.
Related links
Adherence to Mediterranean diet reduces risk of major chronic diseases [Prevention > Prevention; Sep 12, 2008]
Heart disease linked to poor cognitive function in middle age [Brain/Kidney/Peripheral > Brain/Kidney/Peripheral; Jul 23, 2008]
Low HDL-C associated with poor memory [HeartWire > Brain/Kidney/Peripheral; Jun 30, 2008]
High cholesterol linked to increased AD risk [HeartWire > Medscape Medical News; Nov 06, 2006]
Low cholesterol linked to reduced cognitive function [HeartWire > News; Mar 23, 2005]
Lipid metabolism abnormalities observed in brain aging and Alzheimer's disease [HeartWire > News; Feb 15, 2004]

Modest reductions in dietary salt would reap great benefits

Moral of the story: Add just a little less salt while cooking, add even less while eating and it will go a long way.

Modest reductions in dietary salt would reap great benefits
March 17, 2009 | Lisa Nainggolan

Palm Harbor, FL - US researchers say even a small reduction in the amount of salt in the daily diet would have a huge public-health impact. Dr Kirsten Bibbins-Domingo (University of California, San Francisco) and colleagues calculate that cutting just 1 g of salt a day would prevent a quarter of a million new heart-disease cases and 200 000 deaths from any cause over a decade [1].

Bibbins-Domingo told heartwire that "everyone would benefit, but certain groups gain more." These include African Americans, women, and those under 65, she noted. Americans currently eat 9 to 12 g of salt per day, an amount far in excess of the 5 to 6 g per day that is recommended by most health organizations, she said. She reported the new findings in a poster at the AHA 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention last week.

She feels strongly that regulatory efforts will be key to tackling this problem, because 80% of the salt in the US—and other Western nations' diets—comes from processed and prepared foods. "We can't just keep telling patients to get rid of the salt shaker, because that has very little effect."

With these very small changes . . . we will not change the taste of foods or the profit margins of the food industry, but it would be a great benefit for public health.

"We think our study lends support to the idea that this is an area that's really a prime target for public-health types of intervention, including regulatory efforts to restrict salt or force labeling of foods based on their salt content. We hope this would encourage efforts on the part of industry to reduce salt. The experience in other countries suggests that with these very small changes we are describing, we will not change the taste of foods or the profit margins of the food industry, but it would be a great benefit for public health."


A 3-g daily reduction in salt would give same benefits as eliminating smoking

Bibbins-Domingo et al used the Coronary Heart Disease Policy Model, a computer simulation of heart disease in the US adult population, and an extension that assesses stroke, to evaluate the impact of hypothetical policy changes on the health of the nation.

They estimated the impact of an immediate reduction of daily salt intake by 0 to 6 g on the incidence of cardiovascular disease and deaths between 2010 and 2019. In that period, the model suggests that more than 800 000 life-years could be saved for each gram of salt lowered.

"Others have estimated the population benefits of salt reduction; our findings are consistent with these studies and extend them in important ways," she and her colleagues note.

A 3-g daily reduction in the amount of salt consumed would provide morbidity and mortality benefits "on the same order of magnitude as if we could eliminate smoking in the population, and that's a really important point to make," she told heartwire. Such a reduction would result in 6% fewer cases of new heart disease, 8% fewer MIs, and 3% fewer deaths.

Even larger health benefits are projected for African Americans, she says, who are more likely to have high blood pressure and whose blood pressure may be more sensitive to salt: new heart-disease cases would be reduced by 10%, MIs by 13%, and deaths by 6%. Other groups who would gain include women, because of reductions in stroke—as high blood pressure is the major risk factor for stroke—and young people (under 65), who would benefit from a reduction in premature death, because often high blood pressure is the only risk factor in this group, she notes.

Bibbins-Domingo says consumer awareness is also important, so that individuals make more effort to reduce salt in their diets. Experiences in other countries suggest that the combination of government regulations, labeling requirements, voluntary efforts on the part of industry, and increasing consumer awareness of the dangers of consuming too much salt can, in concert, achieve worthwhile improvements. In the UK, for example, a combination of the above managed to achieve a 10% reduction in salt intake, she notes.

"We have to appreciate the scope of this problem and realize that efforts are needed on all these levels," she concludes.

Source
  1. Bibbins-Domingo, Chertow G, Moran A et al. Population reductions in coronary heart disease associated with modest increases in salt intake: projections from the CHD policy model. AHA 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention; March 10-14, 2009; Palm Harbor, FL. Abstract P51.

Thursday, March 5, 2009

adverse clopidogrel and proton-pump inhibitor interaction

Moral of the story: Been hospitalized for heart problems recently? Been given Plavix (clopidogrel) and a proton pump inhibitor? NOT GOOD. Have your physician change your prescriptions immediately. This is just the latest in recent publishings about the adverse interaction.

More data support adverse clopidogrel and proton-pump inhibitor interaction
March 3, 2009 Michael O'Riordan TheHeart.org


Denver, CO - More evidence published this week suggests that the concomitant use of clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) and proton-pump inhibitors (PPIs) attenuates the benefits of antiplatelet therapy and increases the risk of future events. Among discharged acute coronary syndrome (ACS) patients prescribed the two drugs, there was an increased risk of adverse clinical outcomes compared with clopidogrel alone, including higher rates of death or rehospitalization for ACS [1].

"I don't think our study changes the guidelines or the recommendations for clopidogrel use after ACS hospitalization," lead investigator Dr P Michael Ho (Denver Veterans Affairs Medical Center, CO) told heartwire, "but it does suggest, along with other studies, that proton-pump inhibitors shouldn't be prescribed prophylactically just because the patient is on aspirin and clopidogrel. Given the accumulating evidence, this study suggests that unless there is a clear indication for the PPI medication, there might be other stomach medications that patients can take."

The results of the study are published in the March 4, 2009 issue of the Journal of the American Medical Association.FDA issued an early communication about safety review
Clopidogrel is a prodrug converted in the liver to its active form by cytochrome P450 isoenzymes, with P450 2C19 playing a particularly important role. There is evidence suggesting that various PPIs can inhibit P450 2C19, which would alter the effectiveness of clopidogrel and potentially lead to an increased risk of adverse cardiovascular outcomes. As noted by the investigators, many patients treated with clopidogrel and aspirin following ACS are also treated with PPIs to reduce the risk of gastrointestinal bleeding with dual antiplatelet therapy.
In January, the Food and Administration (FDA) announced it was continuing to study the effectiveness of clopidogrel in patients taking other medications, particularly PPIs, as well as in those with genetic variants linked with clopidogrel resistance. Despite the early communication from the FDA, the existing data were insufficient to make firm recommendations, leading investigators to analyze the interaction in a large cohort of Veterans Affairs patients.
In this retrospective cohort study, 8205 patients with ACS taking clopidogrel after discharge from the hospital between 2003 and 2006 were identified. Of these patients, 64% were prescribed a PPI at discharge or during follow-up, while 36% were not prescribed a PPI. Those prescribed a PPI tended to be older and have more comorbid disease, including higher rates of diabetes, prior MI, previous CABG surgery, peripheral vascular disease, and lung and renal disease.

Concomitant use of clopidogrel and a PPI was associated with a 25% greater risk of death or rehospitalization for ACS, the primary end point in this analysis. Individual end points, including rehospitalization for ACS and revascularization procedures, were also significantly increased with the combination, although all-cause mortality was not significantly different between the two treatment regimens. Adverse outcomes following hospital discharge for ACS

Various sensitivity analyses examining time periods of use, as well as a nested case-control analysis, confirmed the findings and suggested it was the interaction of the medications responsible for the increased risk. The increased risk of an adverse outcome associated with the use of clopidogrel and PPI remained statistically significant after researchers excluded those with a history of gastrointestinal bleeding prior to hospitalization for ACS, those who had a bleeding event during hospitalization, and those prescribed an H2-antagonist.

Speaking with heartwire, Ho noted that the risk appears primarily due to recurrent hospitalization for ACS, which is consistent with mechanistic studies suggesting an increased prothrombotic state due to the inhibition of platelet activity with clopidogrel and PPIs. He noted that 8% of patients in this study had a previous history of gastrointestinal bleeding, while 25% had an in-hospital bleed or during follow-up, making them eligible for a PPI. Still, with 64% prescribed a PPI in this study, "it suggests there are a large number of patients prescribed the drug prophylactically," said Ho.

Regarding the lack of mortality risk associated with the interaction, Ho said that researchers had access only to all-cause mortality data and that more detailed causes of death might show a signal, particularly with cardiovascular death.

The researchers also note that 60% of patients taking a PPI were prescribed omeprazole, a drug available over the counter since 2003, and that there was a strong association between its use with clopidogrel and adverse clinical outcomes. Overall, said Ho, the findings highlight the importance of a drug interaction not observed in large clinical trials and suggest that drug surveillance is critical after drug approval to monitor unintended side effects and interactions.

SCAI issues a statement
In light of the findings, the Society for Cardiovascular Angiography and Interventions (SCAI) issued a statement that patients prescribed clopidogrel and other antiplatelet medications after undergoing interventional cardiology procedures should continue taking the drugs unless told to stop by their physician.
An expert consensus document developed by the American College of Cardiology, American Heart Association, and American College of Gastroenterology and published in 2008 notes that PPIs should be the mainstay of treatment and prevention of gastrointestinal ulcers and bleeding in patients on antiplatelet therapy who are at increased risk for the gastrointestinal complications. High-risk patients who might benefit from a PPI include patients with a history of ulcer disease, gastrointestinal bleeding, a need for dual antiplatelet therapy, or an indication for warfarin or other anticoagulants, according to the report.
SCAI recommends physicians continue prescribing dual antiplatelet therapy after stent implantation according to the guidelines and prescribe a PPI medication when there is a clinical indication for it.

Source
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.

Friday, February 27, 2009

Green and Black Tea Consumption and Risk of Stroke. A Meta-Analysis

Moral of the story: Drinking black and green tea can help prevent a stroke. A meta-analysis is an analysis of all the literature on a single topic. This study found that taken all together, studies suggest that 3 cups of tea may be effective.

Green and Black Tea Consumption and Risk of Stroke. A Meta-Analysis

Lenore Arab PhD*;
Weiqing Liu MS; and David Elashoff PhD

From UCLA's School of Medicine, Los Angeles, Calif.

* To whom correspondence should be addressed. E-mail: Larab@ucla.edu.

Background and Purpose—Experimental models of stroke provide consistent evidence of smaller stroke volumes in animals ingesting tea components or tea extracts. To assess whether a similar association of black or green tea consumption with reduced risk is evident in human populations, we sought to identify and summarize all human clinical and observational data on tea and stroke.

Methods—We searched PubMed and Web of Science for all studies on stroke and tea consumption in humans with original data, including estimation or measurement of tea consumption and outcomes of fatal or nonfatal stroke. Data from 9 studies involving 4378 strokes among 194 965 individuals were pooled. The main outcome was the occurrence of fatal or nonfatal stroke. We tested for heterogeneity and calculated the summary effect estimate associated with consumption of ≥3 cups of tea (green or black) per day using random-effects and fixed-effects models for the homogeneous studies. Publication bias was also evaluated.

Results—Regardless of their country of origin, individuals consuming ≥3 cups of tea per day had a 21% lower risk of stroke than those consuming <1> 0.85). The proportion of heterogeneity not explained by chance alone was 23.8%.

Conclusions—Although a randomized clinical trial would be necessary to confirm the effect, this meta-analysis suggests that daily consumption of either green or black tea equaling 3 cups per day could prevent the onset of ischemic stroke.


Key words: black tea • Camelia sinensis • green tea • ischemic stroke • theophylline

Wednesday, February 4, 2009

High resting pulse increases risk of MI, coronary death in women

Moral of the story: know your risk factors. Are you female? Do you have a resting heart rate higher than 75 bpm? Then you are at an increased risk for MI (heart attack) and coronary disease/death. Make sure to take especially good care of your heart if you fall into both of those categories

Heartwire
Clinical cardiology
High resting pulse increases risk of MI, coronary death in women
February 4, 2009

Washington, DC - A high resting heart rate is associated with an increased risk of MI or coronary death in females, a new analysis from the Women's Health Initiative (WHI) shows [1]. Dr Judith Hsia (AstraZeneca, Wilmington, DE, who was at George Washington University when this research was done) and colleagues report the findings online February 3, 2009 in BMJ.

"Multiple studies in men have previously shown that a high heart rate, after adjustment for other potential confounders such as blood pressure and cholesterol, is associated with an increased risk of heart attack and coronary death," Hsia explained to heartwire. "But this is the first demonstration in women that having a high heart rate increases this risk."

She points out that it was only women in the highest quintile (with a heart rate of 76 bpm or higher) who had a significantly increased risk and that there was no relationship between high resting pulse and risk of stroke in this cohort.

In terms of implications for doctors, Hsia says, as physicians already check resting pulse as part of their global cardiovascular risk assessment, "they may just consider this in addition to the factors they already use when deciding how aggressively people need to be managed. If, for example, you have a patient who is reluctant to take something for their blood pressure or cholesterol, maybe they should think again if they have a high resting heart rate."

Association present across ethnic groups, strongest in younger women

In their analysis, Hsia et al identified 2281 women with MI or coronary death and 1877 with stroke over a mean of 7.8 years of follow-up among 129 135 postmenopausal women in the WHI with no history of cardiovascular events. They evaluated associations between resting heart rate and cardiovascular events in Cox regression models adjusted for multiple covariates. Hsia points out that the WHI is one of the few studies to have detailed information on physical activity, which was also adjusted for.

Higher resting heart rate was independently associated with a 26% increased risk of coronary events (hazard ratio 1.26 for highest quintile [>76 bpm] vs lowest quintile [<62 bpm]; p=0.001), but not with stroke (HR 1.01).

The relation between resting pulse and risk of coronary events was stronger in younger postmenopausal women (aged 50 to 64) than in older ones (65 and over), and heart rate was similarly predictive for coronary events across all ethnic groups included in the study, Hsia said.
What's attractive about this analysis is that heart rate is such a low-tech assessment.
The strength of this association, from lowest to highest quintile of heart rate, is less than the association with cigarette smoking or diabetes mellitus, Hsia and colleagues add, but they say it "might be large enough to be clinically meaningful," and they stress that it is independent of physical activity.

"We don't know exactly why this higher heart rate is associated with increased heart-attack risk," Hsia told heartwire. "Heart rate is thought to reflect a balance between the adrenaline side of the system and the vagal side, so it may be that the 'thermostat' is set on the high side for adrenaline in those women who have a higher heart rate.

"What's attractive about this analysis is that heart rate is such a low-tech assessment" compared with more elaborate, time-consuming, and expensive methods to assess autonomic tone, she concludes.

Source
Hsia J, Larson JC, Ockene JK, et al. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 2009; DOI:10.1136/bmj.b219. Available at: http://www.bmj.com.

Friday, January 23, 2009

WomenHeart Series: Depression and the Heart

Moral of the Story: One area of heart health that has been garnering a lot of attention recently in physician circles is the link between depression and cardiovascular disease. This is an in depth discussion about the clinical relationship, which is still unclear, between the two and what screening and preventive actions should be taken. This is specifically about women, however the relationship holds true for men as well.

http://www.theheart.org/article/921585.do

WomenHeart Series: Depression and the Heart
Depression is common among patients with cardiovascular disease (CVD), particularly women. Clinical depression and heightened depressive symptoms have been associated with adverse outcomes in both male and female cardiac patients. The exact mechanisms by which depression affects outcome remain to be elucidated and there is some debate over whether depression precedes or follows cardiac events. Even so, a 2008 AHA Science Advisory supports the need for screening and treating depression in patients with coronary heart disease. Our expert panel discusses the links between depression and CVD and how screening and treatment for depression can be integrated into clinical practice.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate.
SPONSORSHIP STATEMENT
This program is developed in conjunction with WomenHeart: The National Coalition for Women with Heart Disease.
Purpose / goal
The purpose of this activity is to educate clinicians to recognize and treat depression in patients with cardiovascular disease.
Target audience
This program is intended for cardiologists, primary care physicians and other healthcare providers involved in the management of patients with cardiovascular disease.
Educational objectives
At the conclusion of this program, participants will be able to:
Outline the clinical significance of depression in patients with CVD
Review data on the treatment of depression and CV risk
Summarize guidelines for the screening and treatment of depression in patients with CVD
Accreditation statement
Medscape is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Medscape designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Each participant should only claim credit commensurate with the extent of his/her participation in the activity. For questions or assistance, please contact CME@medscape.net

Friday, January 16, 2009

New Thinking on How to Protect the Heart

Moral of the Story: The Mediterranean diet really does work, as proven by a randomized clinical trial (the gold stardard of investigative medicine). The part about C-reactive protein is a bit misleading and I would disagree with Dr. Ozner about getting tested for it. CRP is an indicator but by itself has no effect on heart health. Since you should be following these guidelines anyway there would be no benefit to getting your CRP tested. However, if you are not following the guidelines and you need motivation, get it tested. Otherwise, enjoy some nice fish with veggies cooked in olive oil and you should be good to go.

NY TIMES ARTICLE: http://www.nytimes.com/2009/01/13/health/13brod.html?em

By JANE E. BRODY
Published: January 12, 2009
If last week’s column convinced you that surgery may not be the best way to avoid a heart attack or sudden cardiac death, the next step is finding out what can work as well or better to protect your heart.
Many measures are probably familiar: not smoking, controlling cholesterol and blood pressure, exercising regularly and staying at a healthy weight. But some newer suggestions may surprise you.
It is not that the old advice, like eating a low-fat diet or exercising vigorously, was bad advice; it was based on the best available evidence of the time and can still be very helpful. But as researchers unravel the biochemical reasons for most heart attacks, the advice for avoiding them is changing.
And, you’ll be happy to know, the new suggestions for both diet and exercise are less rigid. The food is tasty, easy to prepare and relatively inexpensive, and you don’t have to sweat for an hour a day to reap the benefits of exercise.
The well-established risk factors for heart disease remain intact: high cholesterol, high blood pressure, smoking, diabetes, abdominal obesity and sedentary living. But behind them a relatively new factor has emerged that may be even more important as a cause of heart attacks than, say, high blood levels of artery-damaging cholesterol.
That factor is C-reactive protein, or CRP, a blood-borne marker of inflammation that, along with coagulation factors, is now increasingly recognized as the driving force behind clots that block blood flow to the heart. Yet patients are rarely tested for CRP, even if they already have heart problems.
Even in people with normal cholesterol, if CRP is elevated, the risk of heart attack is too, said Dr. Michael Ozner, medical director of the Cardiovascular Prevention Institute of South Florida. He thinks that when people have their cholesterol checked, they should also be tested for high-sensitivity CRP.
Diet Revisited
The new dietary advice is actually based on a rather old finding that predates the mantra to eat a low-fat diet. In the Seven Countries Study started in 1958 and first published in 1970, Dr. Ancel Keys of the University of Minnesota and co-authors found that heart disease was rare in the Mediterranean and Asian regions where vegetables, grains, fruits, beans and fish were the dietary mainstays. But in countries like Finland and the United States where plates were typically filled with red meat, cheese and other foods rich in saturated fats, heart disease and cardiac deaths were epidemic.
The finding resulted in the well-known advice to reduce dietary fat and especially saturated fats (those that are firm at room temperature), and to replace these harmful fats with unsaturated ones like vegetable oils. What was missed at the time and has now become increasingly apparent is that the heart-healthy Mediterranean diet is not really low in fat, but its main sources of fat — olive oil and oily fish as well as nuts, seeds and certain vegetables — help to prevent heart disease by improving cholesterol ratios and reducing inflammation.
Virtues Confirmed
It was not until 1999 that the value of a traditional Mediterranean diet was confirmed, when the Lyon Diet Heart Study compared the effects of a Mediterranean-style diet with one that the American Heart Association recommended for patients who had survived a first heart attack.
The study found that within four years, the Mediterranean approach reduced the rates of heart disease recurrence and cardiac death by 50 to 70 percent when compared with the heart association diet.
Several subsequent studies have confirmed the virtues of the Mediterranean approach. For example, a study among more than 3,000 men and women in Greece, published in 2004 by Dr. Christina Chrysohoou of the University of Athens, found that adhering to a Mediterranean diet improved six markers of inflammation and coagulation, including CRP, white blood cell count and fibrinogen.
The same year Kim T. B. Knoops, a nutritionist at Wageningen University in the Netherlands, and co-authors published a study showing that among men and women ages 70 to 90, those who followed a Mediterranean diet and other healthful practices, like not smoking, had a 50 percent lower rate of deaths from heart disease and all causes.
“The Mediterranean diet is one people can stick to,” said Dr. Ozner, author of “The Miami Mediterranean Diet” and “The Great American Heart Hoax” (BenBella, 2008). “The food is delicious, and the ingredients can be found in any grocery store.
“You should make most of the food yourself,” Dr. Ozner added. “When the diet is stripped of lots of processed foods, you ratchet down inflammation. Among my patients, the compliance rate — those who adopt the diet and stick with it — is greater than 90 percent.”
Among foods that help to reduce the inflammatory marker CRP are cold-water fish like salmon, tuna and mackerel; flax seed; walnuts; and canola oil and margarine based on canola oil. Fish oil capsules are also effective. Dr. Ozner recommends cooking with canola oil and using more expensive and aromatic olive oil for salads.
Other aspects of the Mediterranean diet — vegetables, fruits and red wine (or purple grape juice) — are helpful as well. Their antioxidant properties help prevent the formation of artery-damaging LDL cholesterol.
Other Steps
Several recent studies have linked periodontal disease to an increased risk of heart disease, most likely because gum disease causes low-grade chronic inflammation. So good dental hygiene, with regular periodontal cleanings, can help protect your heart as well as your teeth.
Reducing chronic stress is another important factor. The Interheart study, which examined the effects of stress in more than 27,000 people, found that stress more than doubled the risk of heart attacks.
Dr. Joel Okner, a cardiologist in Chicago, and Jeremy Clorfene, a cardiac psychologist, the authors of “The No Bull Book on Heart Disease” (Sterling, 2009), note that getting enough sleep improves the ability to manage stress.
Practicing the relaxation response once or twice a day by breathing deeply and rhythmically in a quiet place with eyes closed and muscles relaxed can help cool the hottest blood. Other techniques Dr. Ozner recommends include meditation, prayer, yoga, self-hypnosis, laughter, taking a midday nap, getting a dog or cat, taking up a hobby and exercising regularly.
He noted that in a 1996 study, just 15 minutes of exercise five days a week decreased the risk of cardiac death by 46 percent.
Even very brief bouts of exercise can be helpful. A British study published in the current American Journal of Clinical Nutrition found that accumulating short bouts — just three minutes each — of brisk walking for a total of 30 minutes a day improved several measures of cardiac risk as effectively as one continuous 30-minute session.
This is the second of two columns on cardiac care. Last week: The drawbacks to interventional cardiology.